Details 7 Related Guidelines / Approvals

Indicated for the adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test.

type

FDA Approval

approval date

2021-10-14

settings
settings
Adjuvant
settings
Stage II
settings
Stage III
source

FDA